Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 373 participants.
Also called NCT01364428
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 373 participants
- Sponsor
- Registry
-
NCT01364428 -
U1111-1119-2518
-
- Other papers using this trial's data
- Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01364428. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-01 (actual). Results posted on 2015-11-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
- Acronym
- BEGIN™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- insulin degludec
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01364428- Content hash
a3d77ade7b9f4f6d386c769acc453cbf72ee554b9427885b1f2e0bd3697e6eb8